MB 11040

Drug Profile

MB 11040

Alternative Names: MB11040

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mazence
  • Developer KT&G Life Sciences
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Immunomodulators; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Inflammation; Menopausal syndrome

Most Recent Events

  • 30 Mar 2016 No recent reports on development identified - Phase-I for Menopausal syndrome and Cancer in South Korea (unspecified route)
  • 28 Mar 2014 No development reported - Preclinical for Inflammation in South Korea (unspecified route)
  • 31 Oct 2013 Phase-I clinical trials in Menopausal syndrome in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top